Astrion's Axient subsidiary will compete for task orders under the STEP 2.0 contract to build modular satellites for the ...

1 MAIA has announced the trial design for an expansion of its THIO-101 pivotal Phase 2 trial in NSCLC to assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L ...

Eager customers lined up outside electronics stores in Tokyo hours in advance to collect their pre-ordered Nintendo Switch 2 video game consoles.Video above: Before the Switch 2, the N64 was the ...

The Karnataka State Cabinet has approved the establishment of Quantum Research Park Phase 2 at the Indian Institute of Science, Bengaluru (IISc), as announced by Karnataka’s information technology (IT ...

SUNBURY — The Sunbury Wetland Ecological Educational Park, or SWEEP, continues to take shape and draw people to the city to walk its trails. The SWEEP project site sits between Line and Race ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In zone 1, you’re warming up for a run, and in zone 5, you’re at an all-out sprint. Recently, zone 2 has gained MVP status among the five zones, thanks in part to longevity gurus like Peter ...

AnaptysBio Inc. (NASDAQ:ANAB) announced that its investigational drug, rosnilimab, demonstrated a best-in-disease profile in ...

NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796 Pioneering small-molecule program, NT-0796, targets chronic ...

June 04, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative ...

Pioneering small-molecule program, NT-0796, targets chronic inflammation and its fundamental role in the complex cycle of weight regulation Oral, brain-penetrant NLRP3 inflammasome inhibitor being ...